SecBot SecBot
8-K ·Filed Apr 14, 2026

JNJ

JOHNSON & JOHNSON
BULLISH
Impact 8/10
Horizonimmediate Processed7mo ago SEC0000200406-26-000076
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The narrow EPS beat and guidance raise suggest underlying strength, particularly in Innovative Medicine. The dividend increase reinforces JNJ's commitment to shareholder returns, making it attractive for income-focused investors.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$240.01
T+0 close · Apr 14, 2026 · via day close
Latest settled
+7.96%
T+60 · $259.10
Vs SPY
−0.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $240.01entry
  2. T+1 · 7mo ago −0.68%α −1.45% · $238.38
  3. T+5 · 7mo ago −5.85%α −7.24% · $225.97
  4. T+20 · 6mo ago −7.74%α −14.04% · $221.43
  5. T+60 · 4mo ago +7.96%α −0.29% · $259.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Johnson & Johnson reported Q1 2026 earnings with adjusted EPS of $2.70, narrowly beating consensus of $2.68, and raised full-year guidance. The company also announced a 3.1% dividend increase, marking its 64th consecutive annual dividend hike.

Key Financial Metrics

EPS
$2.70
est $2.68 · +0.7%
Revenue
$24.1B
est $23.6B · +1.9% · +9.9% YoY
Rating
beat
Gross Margin
66.3%

Key Facts

  • Adjusted EPS of $2.70 vs. consensus of $2.68
  • Raised full-year 2026 guidance for adjusted EPS to $11.55 at midpoint
  • Declared 3.1% dividend increase to $1.34 per share
  • Innovative Medicine segment grew 11.2% with strong performance in oncology and neuroscience

Financial Impact

Adjusted EPS beat by $0.02 and raised guidance

epsguidancedividend

Risk Factors

  • GAAP EPS of $2.14 missed expectations due to litigation-related charges
  • Future performance depends on execution of restructuring programs

Market Snapshot

Price
$235.00
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
63% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000200406-26-000076
Document: a2026q1exhibit991.htm0000200406-26-000076
Document: jnj-20260414.htm0000200406-26-000076
Document: a2026q1exhibit993.htm0000200406-26-000076
Document: 0000200406-26-000076-index-headers.html0000200406-26-000076
Document: 0000200406-26-000076-index.html0000200406-26-000076
Document: 0000200406-26-000076.txt0000200406-26-000076
8-K Data (Synthetic)0000200406-26-000076

Track record

21 reports on JNJ

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
  3. Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
  4. Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
  5. Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
  6. Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
  7. Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
  8. Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
  10. Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026